Cargando…

Overexpression of Platelet-Derived Growth Factor Receptor Α D842V Mutants Prevents Liver Regeneration and Chemically Induced Hepatocarcinogenesis via Inhibition of MET and EGFR

Platelet-derived growth receptor α (PDGFRα) is a key factor in many pathophysiological processes. The expression level of PDGFRα is significantly elevated in the early stage of liver development and maintained at a lower level in adult normal livers. In this study, we constructed a liver-specific PD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Zhao-Qing, Dong, Jian, Li, Mu-Xing, Zhang, Jian-Fei, Bi, Jian-Bin, Ren, Yi-Fan, Zhang, Li-Na, Wu, Rong-Qian, Monga, Satdarshan P.S., Lv, Yi, Zhang, Xu-Feng, Wang, Hai-Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255377/ https://www.ncbi.nlm.nih.gov/pubmed/32489479 http://dx.doi.org/10.7150/jca.44492

Ejemplares similares

Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis
por: Zhou, Yi, et al.
Publicado: (2023)

The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Pten-NOLC1 Fusion Promotes Cancers Involving MET and EGFR Signalings
por: Luo, Jian-Hua, et al.
Publicado: (2020)

Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD
por: Kazi, Julhash U., et al.
Publicado: (2017)

Ductular Reaction and Liver Regeneration: Fulfilling the Prophecy of Prometheus!
por: Monga, Satdarshan P., et al.
Publicado: (2022)

Expression of the oncogenic, constitutive active Platelet-Derived Growth Factor Receptor alpha D842V mutant induces loss of primary cilia
por: Nielsen, BS, et al.
Publicado: (2015)

Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer
por: Mi, J., et al.
Publicado: (2021)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Analysis of Xylose Operon from Paenibacillus polymyxa ATCC842 and Development of Tools for Gene Expression
por: Wang, Zilong, et al.
Publicado: (2022)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
por: Liu, Li, et al.
Publicado: (2021)

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
por: Zhou, Ji, et al.
Publicado: (2023)

PIN1 promoter polymorphism (−842 G>C) contributes to a decreased risk of cancer: Evidence from meta-analysis
por: TAO, LIANG-JUN, et al.
Publicado: (2014)

The −842G/C Polymorphisms of PIN1 Contributes to Cancer Risk: A Meta-Analysis of 10 Case-Control Studies
por: Xu, Hui-Rong, et al.
Publicado: (2013)

The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report
por: He, Shujiao, et al.
Publicado: (2022)

Effects of astragalus injection on different stages of early hepatocarcinogenesis in a two-stage hepatocarcinogenesis model using rats
por: Tang, Qian, et al.
Publicado: (2019)

Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis
por: Bozkaya, Giray, et al.
Publicado: (2012)

Opposing roles of HDAC6 in liver regeneration and hepatocarcinogenesis
por: Phorl, Sophors, et al.
Publicado: (2022)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

Endothelial Wnts regulate β‐catenin signaling in murine liver zonation and regeneration: A sequel to the Wnt–Wnt situation
por: Preziosi, Morgan, et al.
Publicado: (2018)

Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma
por: Ju, Qing, et al.
Publicado: (2021)

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
por: Liam, Chong Kin, et al.
Publicado: (2023)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
por: Peters, T. L., et al.
Publicado: (2021)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M)‐mutant resistance in vitro and in vivo
por: Zhang, Zhang, et al.
Publicado: (2018)

842. Social Resistance Fuels Ebola Transmission in the Eastern Democratic Republic of Congo
por: Mian, Qaasim, et al.
Publicado: (2019)

842. Histoplasmosis : An observational study from northern India in non-HIV population.
por: Swain, Satish, et al.
Publicado: (2023)

Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3
por: Riehle, Kimberly J., et al.
Publicado: (2008)

Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivo.
por: Curtin, N. J., et al.
Publicado: (1983)

Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation
por: Indio, Valentina, et al.
Publicado: (2020)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
por: Sun, Li, et al.
Publicado: (2021)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
por: Yoshida, Ryohei, et al.
Publicado: (2022)

Abnormal expression of HNRNPA3 in multistep hepatocarcinogenesis
por: Ren, Xinlu, et al.
Publicado: (2021)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report
por: Fan, Jun, et al.
Publicado: (2020)

POS-842 EXTRAPOLATION OF BURDEN OF ACUTE KIDNEY INJURY IN HOSPITALISED COVID-19 PATIENTS
por: ARUL ARUMUGAM, P., et al.
Publicado: (2022)

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Gou, Lan-Ying, et al.
Publicado: (2016)

Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice
por: Qiao, Yu, et al.
Publicado: (2018)

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
por: Li, Jing-Wen, et al.
Publicado: (2019)

High expression of c-Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma
por: Jiang, Mei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jqsod4s1t2qotuft3p1qkb2qg2